PT  - JOURNAL ARTICLE
AU  - Bohdana Basina
AU  - Kseniia Bielosludtseva
AU  - Tetyana Pertseva
AU  - Tetiana Kirieieva
AU  - Mariia Krykhtina
AU  - Nataliia Kravhenko
TI  - Fibrinogen like the predictor of COVID-19 pneumonia progression
AID  - 10.1183/13993003.congress-2021.PA517
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA517
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA517.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA517.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - The aim was to estimate the diagnostic and prognostic role of fibrinogen on admission in hospitalized patients with confirmed COVID-19 pneumonia.Materials and methods: 53 patients (age – 59 (52; 65), men – 22 (41,5 %)) hospitalized with COVID-19 pneumonia, divided into 3 groups: group 1 – 36 patients with moderate COVID-19 pneumonia, group 2 – 12 patients with severe, group 3 – 5 patients with critical. General clinical analysis, fibrinogen performed at admissionResults: At admission the level of fibrinogen was higher than norm (2–4 g/l) in 25 (47,1%) of patients, the highest levels had patients with critical course where it exceeds the upper diagnostic maximum in 3 patients (р1-2=0,044, р1-3=0,033, р2-3=0,015 (Fig.1)).Individual analysis showed that 28 patients from group 2 and 3 had progression of COVID-19 pneumonia in dynamic, which was manifested with increased respiratory failure. Mostly of them (18 or 64,2%) had fibrinogen higher than norm. Analysis shows the powerful reliable connection between increased level of fibrinogen at admission and disease progression (OR=4.2; CI=95% (1.2–14.36); p=0.02).Conclusions: 1) serum level of fibrinogen reflects the severity of COVID-19 pneumonia; 2) for moderate and severe hospitalized patients with COVID-19 pneumonia D-dimer could be the predictor of disease progression: increased level of fibrinoogen at admission more than 4 g/l is associated with 4 times higher risk of disease progression.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA517.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).